Patent classifications
A61K38/486
Peptide therapeutics for treating Alzheimer's disease and related conditions
Peptide compounds derived from cathepsin G (CG), neutrophil elastase (NE), and cationic antimicrobial protein of 37 kDa (CAP37), and methods of their use in inhibiting and/or reversing polymerization of amyloid peptide into oligomers and/or fibrils, and/or disaggregating amyloid plaques, and methods of use of the peptide compounds in treatments of, for example, Alzheimer's disease, cerebral amyloid angiopathy, dementia, and/or neuroinflammation, and/or symptoms thereof are disclosed.
REDUCED-PRESSURE TREATMENT SYSTEMS AND METHODS EMPLOYING DEBRIDEMENT MECHANISMS
Reduced-pressure treatment systems and methods are disclosed that employ debridement mechanisms to remove unwanted tissue. In one instance, a reduced-pressure treatment system for treating a tissue site on a patient includes a manifold member for distributing reduced pressure to the tissue site, a support member for disposing proximate the tissue site and the manifold, and a debridement mechanism coupled to the support member. The debridement mechanism is for debriding the tissue site. The system further includes a sealing drape for placing over the tissue site and manifold member. The sealing drape is operable to form a fluid seal over the tissue site and manifold member. The system also includes a reduced-pressure subsystem for delivering a reduced pressure to the sealing drape. The system may further include a chemical-debridement subsystem. Other systems, manifolds, and methods are disclosed.
SYSTEMS AND METHODS FOR EPICARDIAL TISSUE DISTENSION SOLUTIONS
Systems and methods for improving epicardial tissue distension are described. Drug delivery elements can deliver drugs that can dissolve epicardial fat and/or weaken pericardial connective tissue. Distension systems can provide mechanical distension of the pericardium. The drug delivery and the distension systems can be combined to improve epicardial tissue distension.
Methods and compositions related to therapeutic peptides for cancer therapy
Embodiments of the current invention provide a solution to the problems associated with balancing patient toxicity with broad efficacy of cancer therapy. In particular, embodiments are directed to anti-cancer peptides that demonstrate a broad anti-cancer efficacy with a limited toxicity to normal or non-cancer cells.